The Joint Committee on Vaccination and Immunisation (JCVI) is aware that vaccination has an important role in controlling antimicrobial resistance but considers that current models are not sufficiently developed to fully estimate and quantify the potential impact of vaccines on the burden of antimicrobial resistance. Many of the potential benefits of vaccination in relation to antimicrobial resistance (AMR) cannot therefore be easily included in estimates of cost-effectiveness.
The JCVI has suggested that better tools need to be developed to estimate and quantify the potential impact of vaccines in reducing the long-term burden of AMR. This could then inform cost-effectiveness analyses. The National Institute of Health Research, Health Protection Research Unit, based at the London School of Hygiene and Tropical Medicine, is currently working on the development of such models.
As most resistant infections are healthcare associated, the new JCVI Healthcare Associated Infections Working Group, set up to review and provide preliminary advice to JCVI on the potential use of appropriate vaccines in the United Kingdom, will help to address this issue.